Trueblood Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.44M Buy
9,700
+81
+0.8% +$17.4K 0.85% 21
2026
Q1
$2.09M Sell
9,619
-23
-0.2% -$5.1K 0.82% 24
2025
Q4
$2.2M Buy
9,642
+2,793
+41% +$636K 0.86% 20
2025
Q3
$1.59M Buy
6,849
+281
+4% +$57.2K 0.62% 47
2025
Q2
$1.22M Buy
6,568
+262
+4% +$48.7K 0.51% 62
2025
Q1
$1.32M Buy
6,306
+192
+3% +$37.3K 0.61% 49
2024
Q4
$1.09M Sell
6,114
-233
-4% -$42.8K 0.54% 56
2024
Q3
$1.25M Sell
6,347
-27
-0.4% -$5.04K 0.63% 44
2024
Q2
$1.09M Sell
6,374
-330
-5% -$54.7K 0.62% 47
2024
Q1
$1.22M Buy
6,704
+77
+1% +$13.3K 0.7% 40
2023
Q4
$1.03M Buy
+6,627
New +$966K 0.64% 43

Other funds holding ABBV

Trueblood Wealth Management's ABBV Position: Q2 2026 in Review

Trueblood Wealth Management increased its AbbVie (ABBV) stake by 0.84% in Q2 2026, buying an estimated $17.4K and bringing the position to 9,700 shares worth $2.44M. The position accounts for 0.85% of the portfolio, ranked #21.

Trueblood Wealth Management first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Trueblood Wealth Management held 9,700 shares of AbbVie worth $2.44M as of Q2 2026.
  • Trueblood Wealth Management bought 81 AbbVie shares in Q2 2026, an estimated $17.4K.
  • AbbVie made up 0.85% of Trueblood Wealth Management's portfolio in Q2 2026, its #21 holding.
  • Trueblood Wealth Management first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Trueblood Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.